Paper Details

  1. Home
  2. Paper Details

PEGylated interferon beta-1a: meeting an unmet medical need in the treatment of relapsing multiple sclerosis.

Author: BakerDarren P, BrickelmaierMargot, CrossmanMary, DavarGudarz, GlickGabrielle, GronkeRobert S, HitchmanStacy, HuXiao, LernerMichaela, LiuShifang, MillerLarisa, NestorovIvan, OlivierKenneth, PanzaraMichael A, PepinskyRobert Blake, RichmanSandra, SubramanyamMeena, ZhuYing

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

A PEGylated form of interferon beta-1a is being tested for the treatment of relapsing multiple sclerosis. It is administered subcutaneously every 2 or 4 weeks and may offer a safer and more effective treatment option.
Paper Details　
Original Abstract of the Article :
Multiple sclerosis is a chronic autoimmune disease of the central nervous system for which a number of disease-modifying therapies are available, including interferon beta (Avonex®, Rebif®, and Betaseron/Betaferon®), glatiramer acetate (Copaxone®), and an anti-VLA4 monoclonal antibody (Tysabri®). De...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1089/jir.2010.0092

データ提供：米国国立医学図書館（NLM）

PEGylated Interferon Beta-1a: Meeting an Unmet Medical Need

This research explores the development and potential of PEGylated interferon beta-1a, a modified form of interferon beta-1a, as a treatment for relapsing multiple sclerosis. The authors discuss the challenges faced by current therapies, including the need for frequent injections and potential adverse effects. They highlight the potential of PEGylated interferon beta-1a to address these challenges by providing a safe and efficacious treatment with a reduced dosing frequency. The authors describe a clinical trial currently underway to evaluate the safety and efficacy of PEGylated interferon beta-1a in patients with relapsing multiple sclerosis.

A New Oasis in the Desert of Multiple Sclerosis

This research offers a glimmer of hope for patients with relapsing multiple sclerosis. Imagine a vast desert, where current treatments for multiple sclerosis are represented by scattered oases, each with its own limitations. PEGylated interferon beta-1a, like a newly discovered oasis, holds the potential to offer a more accessible and effective treatment option for this debilitating disease.

Navigating the Challenges of Multiple Sclerosis

This research emphasizes the ongoing search for better treatments for multiple sclerosis. Just as a desert traveler must constantly adapt their journey to the changing landscape, researchers are continuously exploring new pathways to effectively manage this complex disease. This research represents a significant step forward in the pursuit of safer and more effective therapies.

Dr.Camel's Conclusion

This research, like a shimmering mirage in the vast desert of multiple sclerosis, offers a glimpse of hope for patients seeking relief from this debilitating condition. The development of PEGylated interferon beta-1a represents a potential breakthrough, offering a more accessible and effective treatment option, akin to discovering a refreshing oasis in the harsh desert landscape.

Date :
  1. Date Completed 2011-03-11
  2. Date Revised 2022-04-08
Further Info :

Pubmed ID

20836711

DOI: Digital Object Identifier

10.1089/jir.2010.0092

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.